Rivaroxaban 2.5 mg BID and Aspirin for Intermittent Claudication in PAD Patients
Status:
Recruiting
Trial end date:
2021-11-30
Target enrollment:
Participant gender:
Summary
This trial is evaluating if rivaroxaban 2.5 mg BID and aspirin 100 mg OD compared to aspirin
alone improves on intermittent claudication distance in PAD patients.